Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.35 USD
-2.01%
Market Closed
Updated:
Apr 25, 2024
Section:
Relative Value
The Relative Value of one
EDIT
stock under the Base Case scenario is
11.51
USD.
Compared to the current market price of 5.35 USD,
Editas Medicine Inc
is
Undervalued by 54%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EDIT
Relative Value
Base Case
11.51
USD
Undervaluation 54%
Valuation Multiples
Multiples Across Competitors
EDIT Competitors Multiples
Editas Medicine Inc Competitors
Editas Medicine Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
437.5m USD | 5.6 | -2.9 | -0.7 | -0.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
296.3B USD | 5.5 | 61.5 | 13.3 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.3B USD | 10.5 | 28.5 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
99.2B USD | 7.6 | 25.1 | 16.7 | 18.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.5B AUD | 6.2 | 35.4 | 21.4 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.6B USD | 3.1 | 14.8 | 8.1 | 10.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.6B USD | 6.1 | -8.8 | -9.3 | -7.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
29.3B USD | 3 | 25.2 | 13.8 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
37.2T KRW | 17.1 | 69.4 | 42.6 | 58.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
